The only ACE inhibitor significantly associated with a reduction in AAA growth rate in the drug-specific multivariate models, using the stringent Bonferroni multiple testing correction, was lisinopril (model 3 −0.363 mm/year, P = 0.00169). The gene discussed is ACE; the disease is triple-A syndrome.